<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/DD21B8FC-26A6-4A3A-9A23-207B6667CB41"><gtr:id>DD21B8FC-26A6-4A3A-9A23-207B6667CB41</gtr:id><gtr:name>University of Pittsburgh</gtr:name><gtr:address><gtr:line1>University of Pittsburgh</gtr:line1><gtr:line4>Pittsburgh</gtr:line4><gtr:line5>Pennsylvania</gtr:line5><gtr:postCode>PA 15260</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:department>Dept of Medicine</gtr:department><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/DD21B8FC-26A6-4A3A-9A23-207B6667CB41"><gtr:id>DD21B8FC-26A6-4A3A-9A23-207B6667CB41</gtr:id><gtr:name>University of Pittsburgh</gtr:name><gtr:address><gtr:line1>University of Pittsburgh</gtr:line1><gtr:line4>Pittsburgh</gtr:line4><gtr:line5>Pennsylvania</gtr:line5><gtr:postCode>PA 15260</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/D755320B-897A-4664-984C-1480D6978A96"><gtr:id>D755320B-897A-4664-984C-1480D6978A96</gtr:id><gtr:firstName>Robert</gtr:firstName><gtr:surname>Lechler</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/E04275DF-111E-44B5-B7F0-FECA4478B406"><gtr:id>E04275DF-111E-44B5-B7F0-FECA4478B406</gtr:id><gtr:firstName>Anthony</gtr:firstName><gtr:surname>Dorling</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0401591"><gtr:id>E7B4C455-247F-4382-A7D2-68BF8D24D17A</gtr:id><gtr:title>Targeted inhibition of coagulation - an anti-inflammatory approach to prolonging organ graft survival</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0401591</gtr:grantReference><gtr:abstractText>Organ transplantation is a cost-effective treatment for severe kidney, heart and liver disease and patients often return to living a relatively normal life. There is a worldwide effort to increase the supply or organs, so that more patients can benefit, but this has inevitably involved using some organs that previously were deemed medically unsuitable and these organs have suboptimal function. At the same time, transplanted organs don?t last forever. Instead, many suffer an insidious decline in function. In the case of kidney transplantation, most patients with this ?chronic rejection? eventually return to dialysis. This proposal will investigate whether blood-clotting proteins are involved in the inflammatory processes that cause poor performance and premature failure. There is good reason to think that some members of this family will be involved, because of their roles in other types of inflammation. The work being proposed will be entirely in mice, for three main reasons. First, much is already known about the mechanisms of transplant dysfunction in mice and there are many similarities with the same mechanisms in humans. Second, the use of genetically modified strains will greatly simplify the interpretation of many of the results. Third, we have the necessary expertise and knowledge to perform these experiments in rodents. We believe that this work will show the fundamental roles that members of this family of proteins have in determining how well transplanted organs work and how long they last. Although there are many systemic anticoagulants that inhibit the function of these clotting proteins, current therapies can have severe side effects, including a risk of life-threatening bleeding. Therefore, working out a safe way to inhibit the function of these proteins will be vital if the knowledge gained in this project is to be turned into a therapeutic strategy. Our method, which we?ll be able to test in this work, involves targeting the anticoagulants to exactly the cells or tissues where they are needed, thereby avoiding the potentially dangerous side effects. This might be on the transplanted organ, or might be on recipient cells. Either way, we anticipate that once we?ve established the basis for this strategy, new cell-targeted, protein-based treatments could be made and tested almost immediately, using current technology, for pre-clinical testing. Enhancing the early performance of transplanted organs and preventing premature organ failure will have a significant, immediate and lasting impact on the lives of many thousands of patients.</gtr:abstractText><gtr:technicalSummary>Although organ transplantation is a therapeutic success, novel solutions are required to prevent premature organ failure, particularly as the donor pool expands to include organs from so-called marginal donors . This proposal will investigate the importance of coagulation proteins (CP) in the inflammatory and immune mechanisms that drive organ dysfunction. It builds on an appreciation that CP have important inflammatory functions and an understanding of the critical role that innate factors play in shaping adaptive immune responses. The specific objectives are to; a) define how CP are involved in ischaemia reperfusion injury; b) investigate the hypothesis that CP play a role in determining whether T cells are activated or tolerised; c) explore the hypothesis that CP play a critical role in antibody-mediated (humoral) rejection through activation of specific protease activated receptors (PAR) as well as through intravascular fibrin deposition; d) explore the role of tissue factor and CP in the recruitment and expansion of neointimal cells in the arteriosclerosis of chronic rejection; e) investigate, in each of the above, whether targeted expression of anticoagulants on relevant donor or recipient cells can minimise allograft dysfunction. A combination of in vitro and in vivo approaches will be used, making optimum use of cells and tissues from relevant gene-knockout (KO) and transgenic mice that are available for this study, including PAR-KO, fibrinogen-KO and strains expressing anticoagulants on CD31+ cells (including endothelial cells) or vascular smooth muscle cells. An important aspect of the work will be to differentiate how donor (graft) and recipient elements contribute to the activation of CP and to distinguish the pathological effects of CP on the graft from those on recipient elements. This will be achieved using a combination of bone marrow reconstitution and appropriate choice of recipient/donor combinations so that the KO or transgenic phenotype is expressed on different cellular components. These studies will determine whether inhibiting CP can limit allograft dysfunction and promote long-term organ survival. Consequently, they will establish the foundation for a novel therapeutic strategy, based on expressing anticoagulant proteins in a highly targeted, cell-specific manner, an approach that would maximise therapeutic benefit but obviate the serious difficulties associated with systemic anticoagulation, most importantly severe bleeding. We anticipate that pre-clinical testing of the strategy could follow immediately on from this project and that it will prove to be safe and effective at enhancing organ performance and prolonging graft survival.</gtr:technicalSummary><gtr:fund><gtr:end>2008-10-02</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2005-10-03</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>590999</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Pittsburgh</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Thomas E Starzl Transplantation Institute</gtr:department><gtr:description>NIH Xenotransplantation at Pittsburgh</gtr:description><gtr:id>61C52085-5A46-4528-AC51-67BA49C48D75</gtr:id><gtr:impact>Multiple papers, reported elsewhere - 1st author Lin CC</gtr:impact><gtr:partnerContribution>PhD student to work/train in my lab. Collaboration to supply membrane tethered hirulog (thrombalexin) 2013</gtr:partnerContribution><gtr:piContribution>Collaborator on NIH-funded Xenotransplantation programme. Latterly, advisor to renewed prgramme</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Frontiers in Transplantation Course</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>B5142385-6C52-4C2C-B2C0-354E05E0CD05</gtr:id><gtr:impact>A course for clinicians and scientists interested in translational transplantation research. Attended by more than 80 people in 2014. I was highest rated speaker in 2015.
Second URL relating to 2013 course: https://www.youtube.com/watch?v=ZlzUAzOj47A

Extremely good feedback scores form participants has ensured we will make this an annual event</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>workshop facilitator</gtr:presentationType><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>https://www.youtube.com/watch?v=dRnOEYs9hCQ</gtr:url><gtr:year>2011,2012,2013,2014,2015</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>1000000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Project Grant</gtr:description><gtr:end>2013-03-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>582A72E0-086E-4E6F-9246-AF846C63215A</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>88000</gtr:amountPounds><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project Grant/Roche Organ Transplantation Research Fund</gtr:description><gtr:fundingOrg>Roche Organ Transplantation Research Foundation (ROTRF)</gtr:fundingOrg><gtr:id>F198EFA4-20B5-4E10-89B3-4409C981E495</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>200000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project Grant/Garfield Weston Foundation</gtr:description><gtr:fundingOrg>Garfield Weston Foundation</gtr:fundingOrg><gtr:id>8E105B3F-4495-4B6A-B0D2-94944367D55D</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>60000</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project Grant</gtr:description><gtr:fundingOrg>Roche</gtr:fundingOrg><gtr:id>C2C2FC5C-C27E-4098-8D25-8FD83F63C0B6</gtr:id><gtr:sector>Private</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>130213</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>King's Commercialisation Institute</gtr:department><gtr:description>King's Health Accelerator Award</gtr:description><gtr:end>2017-07-02</gtr:end><gtr:fundingOrg>King's College London (KCL)</gtr:fundingOrg><gtr:id>D4A1B5AA-1231-4796-9451-8E03364B9A3D</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1300000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Translation Award (Co-applicant with Richard Smith)</gtr:description><gtr:end>2015-12-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:id>42BD374C-FB03-4B3D-93F3-082FD04CAC9A</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>Novel cell-tethered anticoagulants that were based in principle on the genetic tethering that we used in our early experiments</gtr:description><gtr:id>24947FBD-E07A-44D0-942E-A19939E294FA</gtr:id><gtr:impact>Has been used to secure Wellcome Trust money to take these compounds through clinical development</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:patentId>WO2011027175</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Novel Antithrombotic Compounds</gtr:title><gtr:yearProtectionGranted>2011</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:description>Work from a previous MRC programme grant on which I was a co-applicant (lead, Professor Robert Lechler), has led directly to the development of a new line of transgenic pig. These animals express human tissue factor pathway inhibitor and have been made and bred for xenotransplantation by the American Company Revivicor</gtr:description><gtr:id>1E4C1142-BD3C-4983-BFA9-73A06E5E383E</gtr:id><gtr:impact>None yet, but expected in near future, as organs from these pigs undergo preclinical testing in primates</gtr:impact><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>TFPI-Transgenic pig</gtr:title><gtr:type>Therapeutic Intervention - Cellular and gene therapies</gtr:type><gtr:yearDevCompleted>2008</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>membrane tethered hirulog, developed directly because of our work with the hirudin-trangenic mice.</gtr:description><gtr:id>692A63FC-AFB6-41E3-BC25-C7A907173696</gtr:id><gtr:impact>none yet</gtr:impact><gtr:stage>Refinement.  Non-clinical</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Thrombalexin</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2012</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Mice generated in 1990s under a previous MRC grant held by Robert Lechler are now held by my group</gtr:description><gtr:id>AA1A8F54-276F-45CA-8C32-40EB7517D8C7</gtr:id><gtr:impact>New collaboration and line of investigation in liver disease resulted in abstract at international meeting, and seminar by me at St Mary's. Will result in a paper</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>supply of Tg mice</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type><gtr:yearFirstProvided>2011</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/AAFA87FE-07BA-4FFD-ABD1-1E0DAD169DBB"><gtr:id>AAFA87FE-07BA-4FFD-ABD1-1E0DAD169DBB</gtr:id><gtr:title>A pig allograft model of antibody-mediated rejection.</gtr:title><gtr:parentPublicationTitle>Transplant immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5c997cecf8035d08dc1ecad96c6b4dc7"><gtr:id>5c997cecf8035d08dc1ecad96c6b4dc7</gtr:id><gtr:otherNames>Herbert PE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0966-3274</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/04754904-DE35-4B1E-8ED7-C4DEAC690024"><gtr:id>04754904-DE35-4B1E-8ED7-C4DEAC690024</gtr:id><gtr:title>Extraanatomic stents for transplant ureteric stenosis.</gtr:title><gtr:parentPublicationTitle>The British journal of radiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/244b0a2578448092ccd11184af7f051a"><gtr:id>244b0a2578448092ccd11184af7f051a</gtr:id><gtr:otherNames>Olsburgh J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0007-1285</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/EBFC3CCD-1A7C-4EE0-BECD-51312BB2ED8E"><gtr:id>EBFC3CCD-1A7C-4EE0-BECD-51312BB2ED8E</gtr:id><gtr:title>Donor HO-1 expression inhibits intimal hyperplasia in unmanipulated graft recipients: a potential role for CD8+ T-cell modulation by carbon monoxide.</gtr:title><gtr:parentPublicationTitle>Transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f6fe5e22b965877bdd9a00288fe733ad"><gtr:id>f6fe5e22b965877bdd9a00288fe733ad</gtr:id><gtr:otherNames>Clarke HM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0041-1337</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A0479391-82F0-402B-9E41-62EE18CE5151"><gtr:id>A0479391-82F0-402B-9E41-62EE18CE5151</gtr:id><gtr:title>B-lymphocytes support and regulate indirect T-cell alloreactivity in individual patients with chronic antibody-mediated rejection.</gtr:title><gtr:parentPublicationTitle>Kidney international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/25ee74e60fac27a1dbf2c03b22f0cff8"><gtr:id>25ee74e60fac27a1dbf2c03b22f0cff8</gtr:id><gtr:otherNames>Shiu KY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0085-2538</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0CA2EAAD-437E-48D8-BE83-C6F18FFFC7DA"><gtr:id>0CA2EAAD-437E-48D8-BE83-C6F18FFFC7DA</gtr:id><gtr:title>The interface between coagulation and immunity.</gtr:title><gtr:parentPublicationTitle>American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/55f40bc5b0102e5288d97d23e4c64c60"><gtr:id>55f40bc5b0102e5288d97d23e4c64c60</gtr:id><gtr:otherNames>Shrivastava S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1600-6135</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8AB687BD-E06D-4AEE-9BEC-9C958F1B329D"><gtr:id>8AB687BD-E06D-4AEE-9BEC-9C958F1B329D</gtr:id><gtr:title>Reply to 'Critics slam Russian trial to test pig pancreas for diabetes'.</gtr:title><gtr:parentPublicationTitle>Nature medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5e14426e549812bf23e31abc2f8d2b8c"><gtr:id>5e14426e549812bf23e31abc2f8d2b8c</gtr:id><gtr:otherNames>Sykes M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1078-8956</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/380BC7D0-9376-4240-8BC2-087E936A68A2"><gtr:id>380BC7D0-9376-4240-8BC2-087E936A68A2</gtr:id><gtr:title>Critical roles for thrombin in acute and chronic inflammation.</gtr:title><gtr:parentPublicationTitle>Journal of thrombosis and haemostasis : JTH</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/2ef91a6d242b3418b3065118aa4f2f60"><gtr:id>2ef91a6d242b3418b3065118aa4f2f60</gtr:id><gtr:otherNames>Chen D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1538-7836</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/999D3174-5FDE-4C63-9DA3-E5D4AE106CDD"><gtr:id>999D3174-5FDE-4C63-9DA3-E5D4AE106CDD</gtr:id><gtr:title>Expression of tissue factor and initiation of clotting by human platelets and monocytes after incubation with porcine endothelial cells.</gtr:title><gtr:parentPublicationTitle>Transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/da775c3c3de734a3fc6025ab4f8f7751"><gtr:id>da775c3c3de734a3fc6025ab4f8f7751</gtr:id><gtr:otherNames>Lin CC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0041-1337</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F4CC3940-C1BD-4F98-9218-733B2FDB5573"><gtr:id>F4CC3940-C1BD-4F98-9218-733B2FDB5573</gtr:id><gtr:title>Protease-activated receptor-2 signalling by tissue factor on dendritic cells suppresses antigen-specific CD4+ T-cell priming.</gtr:title><gtr:parentPublicationTitle>Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/55f40bc5b0102e5288d97d23e4c64c60"><gtr:id>55f40bc5b0102e5288d97d23e4c64c60</gtr:id><gtr:otherNames>Shrivastava S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0019-2805</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A99B512C-7901-4161-921B-EA9F3D42C462"><gtr:id>A99B512C-7901-4161-921B-EA9F3D42C462</gtr:id><gtr:title>Alpha1,3-galactosyltransferase gene-knockout pigs for xenotransplantation: where do we go from here?</gtr:title><gtr:parentPublicationTitle>Transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8470273c8d246493ca365be348646c63"><gtr:id>8470273c8d246493ca365be348646c63</gtr:id><gtr:otherNames>Cooper DK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0041-1337</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/CB7964EF-0B3C-449C-95CB-DF13FB4F9532"><gtr:id>CB7964EF-0B3C-449C-95CB-DF13FB4F9532</gtr:id><gtr:title>Thrombalexin: use of a cytotopic anticoagulant to reduce thrombotic microangiopathy in a highly sensitized model of kidney transplantation.</gtr:title><gtr:parentPublicationTitle>American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/722c4ac63ded662dc422a0a61495e934"><gtr:id>722c4ac63ded662dc422a0a61495e934</gtr:id><gtr:otherNames>Manook M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1600-6135</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/13B2A0DC-3C4E-4869-AFDF-3B9A6B4B079D"><gtr:id>13B2A0DC-3C4E-4869-AFDF-3B9A6B4B079D</gtr:id><gtr:title>ABO incompatible living renal transplantation with a steroid sparing protocol.</gtr:title><gtr:parentPublicationTitle>Transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/00abd58e141af3e5cfb79f714fdccd73"><gtr:id>00abd58e141af3e5cfb79f714fdccd73</gtr:id><gtr:otherNames>Galliford J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0041-1337</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D7E121CC-3C22-47F8-8A0A-E00DBFF489BF"><gtr:id>D7E121CC-3C22-47F8-8A0A-E00DBFF489BF</gtr:id><gtr:title>Protease-activated receptor 1 activation is necessary for monocyte chemoattractant protein 1-dependent leukocyte recruitment in vivo.</gtr:title><gtr:parentPublicationTitle>The Journal of experimental medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/2ef91a6d242b3418b3065118aa4f2f60"><gtr:id>2ef91a6d242b3418b3065118aa4f2f60</gtr:id><gtr:otherNames>Chen D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-1007</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A9E68EAE-D6EF-4F6D-BABD-1B0B431B0982"><gtr:id>A9E68EAE-D6EF-4F6D-BABD-1B0B431B0982</gtr:id><gtr:title>Recipient tissue factor expression is associated with consumptive coagulopathy in pig-to-primate kidney xenotransplantation.</gtr:title><gtr:parentPublicationTitle>American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/da775c3c3de734a3fc6025ab4f8f7751"><gtr:id>da775c3c3de734a3fc6025ab4f8f7751</gtr:id><gtr:otherNames>Lin CC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1600-6135</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/30F4FEB2-62E4-4823-85BE-F0FAEFCF397E"><gtr:id>30F4FEB2-62E4-4823-85BE-F0FAEFCF397E</gtr:id><gtr:title>Role of P-selectin and P-selectin glycoprotein ligand-1 interaction in the induction of tissue factor expression on human platelets after incubation with porcine aortic endothelial cells</gtr:title><gtr:parentPublicationTitle>Xenotransplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b62a6dbdac2e80fac6849082ae2e6a1c"><gtr:id>b62a6dbdac2e80fac6849082ae2e6a1c</gtr:id><gtr:otherNames>Ezzelarab M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C94EB50D-63D8-41EC-B7BF-6C63AC493327"><gtr:id>C94EB50D-63D8-41EC-B7BF-6C63AC493327</gtr:id><gtr:title>Potential factors influencing the development of thrombocytopenia and consumptive coagulopathy after genetically modified pig liver xenotransplantation.</gtr:title><gtr:parentPublicationTitle>Transplant international : official journal of the European Society for Organ Transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7b6ed6b6741cefbb67001d899975a0ee"><gtr:id>7b6ed6b6741cefbb67001d899975a0ee</gtr:id><gtr:otherNames>Ekser B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0934-0874</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/4353B5F3-59B5-4BEC-AE76-4CA764A15613"><gtr:id>4353B5F3-59B5-4BEC-AE76-4CA764A15613</gtr:id><gtr:title>Regulation of rat and human T-cell immune response by pharmacologically modified dendritic cells.</gtr:title><gtr:parentPublicationTitle>Transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/83797bc72fdb7306dd72249479e604e6"><gtr:id>83797bc72fdb7306dd72249479e604e6</gtr:id><gtr:otherNames>Fazekasova H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0041-1337</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8ACD0FB1-EA1D-433A-B8FB-377C62223948"><gtr:id>8ACD0FB1-EA1D-433A-B8FB-377C62223948</gtr:id><gtr:title>Progenitor cells and vascular disease.</gtr:title><gtr:parentPublicationTitle>Cell proliferation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/dda8817281a5557ec88ee4eb5459720d"><gtr:id>dda8817281a5557ec88ee4eb5459720d</gtr:id><gtr:otherNames>Jevon M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0960-7722</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/CE62459B-6BC3-4573-B097-8146FF10DEB1"><gtr:id>CE62459B-6BC3-4573-B097-8146FF10DEB1</gtr:id><gtr:title>Postinjury vascular intimal hyperplasia in mice is completely inhibited by CD34+ bone marrow-derived progenitor cells expressing membrane-tethered anticoagulant fusion proteins.</gtr:title><gtr:parentPublicationTitle>Journal of thrombosis and haemostasis : JTH</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/2ef91a6d242b3418b3065118aa4f2f60"><gtr:id>2ef91a6d242b3418b3065118aa4f2f60</gtr:id><gtr:otherNames>Chen D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1538-7836</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E14A3BB5-43E9-47E3-8178-091B5E4E788C"><gtr:id>E14A3BB5-43E9-47E3-8178-091B5E4E788C</gtr:id><gtr:title>An ex-vivo model for hypothermic pulsatile perfusion of porcine pancreata: hemodynamic and morphologic characteristics.</gtr:title><gtr:parentPublicationTitle>Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b973fa8ce3231c5e3004cf4a44147b03"><gtr:id>b973fa8ce3231c5e3004cf4a44147b03</gtr:id><gtr:otherNames>Karcz M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1304-0855</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C31E71DD-9C37-43F2-977C-1963CD4F784D"><gtr:id>C31E71DD-9C37-43F2-977C-1963CD4F784D</gtr:id><gtr:title>NK-cell-dependent acute xenograft rejection in the mouse heart-to-rat model.</gtr:title><gtr:parentPublicationTitle>Xenotransplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/2ef91a6d242b3418b3065118aa4f2f60"><gtr:id>2ef91a6d242b3418b3065118aa4f2f60</gtr:id><gtr:otherNames>Chen D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0908-665X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7CF0930C-1B25-4A3B-A6AD-10A60CA47E09"><gtr:id>7CF0930C-1B25-4A3B-A6AD-10A60CA47E09</gtr:id><gtr:title>All anti-HBc-positive, HBsAg-negative dialysis patients on the transplant waiting list should be regarded as at risk of hepatitis B reactivation post-renal transplantation--report of three cases from a single centre.</gtr:title><gtr:parentPublicationTitle>Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/dbf0dbec4918649bc8adba66e1c5a888"><gtr:id>dbf0dbec4918649bc8adba66e1c5a888</gtr:id><gtr:otherNames>Roberts RC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0931-0509</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E4292FF2-29E3-4442-810E-EFC55D29779F"><gtr:id>E4292FF2-29E3-4442-810E-EFC55D29779F</gtr:id><gtr:title>Inhibition of thrombin receptor signaling on a-smooth muscle actin(+) CD34(+) progenitors leads to repair after murine immune vascular injury.</gtr:title><gtr:parentPublicationTitle>Arteriosclerosis, thrombosis, and vascular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/2ef91a6d242b3418b3065118aa4f2f60"><gtr:id>2ef91a6d242b3418b3065118aa4f2f60</gtr:id><gtr:otherNames>Chen D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1079-5642</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/372FD10B-46AD-4289-9C58-C8E93D818909"><gtr:id>372FD10B-46AD-4289-9C58-C8E93D818909</gtr:id><gtr:title>Exogenous interferon-gamma immunotherapy for invasive fungal infections in kidney transplant patients.</gtr:title><gtr:parentPublicationTitle>American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f1bcaf5967d9e114942c20e54388995f"><gtr:id>f1bcaf5967d9e114942c20e54388995f</gtr:id><gtr:otherNames>Armstrong-James D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1600-6135</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6EF7D944-D417-4DBF-8D21-52F15C8B717D"><gtr:id>6EF7D944-D417-4DBF-8D21-52F15C8B717D</gtr:id><gtr:title>Factor VII promotes hepatocellular carcinoma progression through ERK-TSC signaling.</gtr:title><gtr:parentPublicationTitle>Cell death discovery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/80404e8d80b50345edfbea7637454854"><gtr:id>80404e8d80b50345edfbea7637454854</gtr:id><gtr:otherNames>Tsai MC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2058-7716</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3B3F0572-E510-435E-A1B2-CDD16626D347"><gtr:id>3B3F0572-E510-435E-A1B2-CDD16626D347</gtr:id><gtr:title>Clinical trial of islet xenotransplantation in Mexico.</gtr:title><gtr:parentPublicationTitle>Xenotransplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5e14426e549812bf23e31abc2f8d2b8c"><gtr:id>5e14426e549812bf23e31abc2f8d2b8c</gtr:id><gtr:otherNames>Sykes M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0908-665X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/186784FB-C5BF-4AD6-A91A-8D9FB2B3AB1E"><gtr:id>186784FB-C5BF-4AD6-A91A-8D9FB2B3AB1E</gtr:id><gtr:title>Smooth muscle cells in porcine vein graft intimal hyperplasia are derived from the local vessel wall.</gtr:title><gtr:parentPublicationTitle>Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/dda8817281a5557ec88ee4eb5459720d"><gtr:id>dda8817281a5557ec88ee4eb5459720d</gtr:id><gtr:otherNames>Jevon M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1054-8807</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0F78DCFD-F666-43AD-BC3D-F68456979B6E"><gtr:id>0F78DCFD-F666-43AD-BC3D-F68456979B6E</gtr:id><gtr:title>Response to Valdes-Gonzalez ''Clinical trial of islet xenotransplantation in Mexico''.</gtr:title><gtr:parentPublicationTitle>Xenotransplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5e14426e549812bf23e31abc2f8d2b8c"><gtr:id>5e14426e549812bf23e31abc2f8d2b8c</gtr:id><gtr:otherNames>Sykes M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0908-665X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8069E3C0-F4DB-48B6-AE39-F9D437E93A19"><gtr:id>8069E3C0-F4DB-48B6-AE39-F9D437E93A19</gtr:id><gtr:title>Enhanced effect of inhibition of thrombin on endothelium in murine endotoxaemia: specific inhibition of thrombocytopenia.</gtr:title><gtr:parentPublicationTitle>Thrombosis research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/2ef91a6d242b3418b3065118aa4f2f60"><gtr:id>2ef91a6d242b3418b3065118aa4f2f60</gtr:id><gtr:otherNames>Chen D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0049-3848</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F411E61F-610B-45F8-B43B-118B14BC5EDD"><gtr:id>F411E61F-610B-45F8-B43B-118B14BC5EDD</gtr:id><gtr:title>Atorvastatin or transgenic expression of TFPI inhibits coagulation initiated by anti-nonGal IgG binding to porcine aortic endothelial cells.</gtr:title><gtr:parentPublicationTitle>Journal of thrombosis and haemostasis : JTH</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/da775c3c3de734a3fc6025ab4f8f7751"><gtr:id>da775c3c3de734a3fc6025ab4f8f7751</gtr:id><gtr:otherNames>Lin CC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1538-7836</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/067F3251-C55F-46DE-A261-3EEF2C1F111D"><gtr:id>067F3251-C55F-46DE-A261-3EEF2C1F111D</gtr:id><gtr:title>Regenerative repair after endoluminal injury in mice with specific antagonism of protease activated receptors on CD34+ vascular progenitors.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/2ef91a6d242b3418b3065118aa4f2f60"><gtr:id>2ef91a6d242b3418b3065118aa4f2f60</gtr:id><gtr:otherNames>Chen D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0401591</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>78E3B265-B307-4D06-9AB7-1F69471E721F</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>5.4  Surgery</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>